

## SCIENTIFIC PROGRAM (as of June 1, 2019)

---

### Tuesday, June 18, 2019

---

- 08:30 – 17:10  
Auditorium  
(USI Università)
- CLOSED WORKSHOP - BRIDGING LIQUID BIOPSY INTO MANAGEMENT OF LYMPHOMA PATIENTS: DEVELOPMENT OF FRAMEWORKS FOR CLINICAL RESEARCH AND RECOMMENDATIONS FOR CLINICAL PRACTICE**  
Co-chairs: D. Rossi, Bellinzona (Switzerland), W.H. Wilson, Bethesda, MD (USA) and E. Zucca, Bellinzona (Switzerland)  
Organized in co-operation with the American Association for Cancer Research – AACR and the European School of Oncology – ESO  
and with the endorsement of the Leukemia & Lymphoma Society - LLS  
**by invitation only**
- 15:00 – 17:15  
Aula Magna  
(USI Università)
- WORKSHOP – NEW GUIDELINES FROM THE INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP - ILROG**  
Organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG  
**open to all 15-ICML attendees**
- PART 1 – NEW GUIDELINES FROM ILROG**  
Chair: L. Specht, Copenhagen (Denmark)
- 15:00
- RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA  
A. Ng, Boston, MA (USA)
- 15:15
- SOLITARY PLASMACYTOMA AND MULTIPLE MYELOMA  
R. Tsang, Toronto (Canada)
- 15:30
- IMAGING IN RADIATION THERAPY FOR LYMPHOMA  
G. Mikhaeel, London (UK)
- 15:45
- PROTON THERAPY FOR MEDIASTINAL LYMPHOMAS  
B.S. Dabaja, Houston, TX (USA)
- 16:00
- DISCUSSION
- 16:15
- COFFEE BREAK** *inside Aula Magna (USI Università), for attendees*
- PART 2 – PANEL DISCUSSION**  
Led by J. Plastaras, Philadelphia, PA (USA)
- 16:30
- FUTURE GUIDELINES TO BE DEVELOPED; ISSUES TO BE CONSIDERED IN ILROG GUIDELINES
- 16:50
- HOW TO DISSEMINATE AND USE ILROG GUIDELINES

---

## Wednesday, June 19, 2019

---

<b>08:30 – 09:15</b>	Article Nr	<b>“MEET THE PROFESSOR” SESSIONS</b> 🏢 <i>5 parallel sessions</i>
Room A	EB09	MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD? S.V. Rajkumar, Rochester, MN (USA) <i>repeated on Thursday, June 20, in Room B</i>
Room B	EB10	THE MODERN APPROACH TO MANTLE CELL LYMPHOMA S. Rule, Plymouth (UK) <i>repeated on Thursday, June 20, in Room A</i>
Cinema Corso	EB07	MANAGING THE TOXICITIES OF CAR T-CELL THERAPY S.S. Neelapu, Houston, TX (USA) <i>repeated on Friday, June 21, in Auditorium (USI Università)</i>
Auditorium (USI Università)	EB01	PCNSL, A CURABLE DISEASE T.T. Batchelor, Boston, MA (USA) <i>repeated on Thursday, June 20, in Cinema Corso</i>
Aula Magna (USI Università)	EB12	WHAT WE SHOULD KNOW ABOUT NK/T-CELL LYMPHOMAS W. Zhao, Shanghai (China) <i>offered only once</i>
<b>09:00 – 12:00</b> Marquee		<b>POSTER SESSION SET UP</b>
<b>09:30 – 10:15</b>		<i>5 parallel sessions</i>
Room A	EB02	DOUBLE HIT LYMPHOMA, SO WHAT? A. Davies, Southampton (UK) <i>repeated on Friday, June 21, in Room B</i>
Room B	EB05	HOW TO APPROACH CLL IN CLINICAL PRACTICE M. Hallek, Cologne (Germany) <i>repeated on Friday, June 21, in Room A</i>
Cinema Corso	EB11	LIQUID BIOPSY IN NON-HODGKIN'S LYMPHOMA W.H. Wilson, Bethesda, MD (USA) <i>repeated on Thursday, June 20, in Auditorium (USI Università)</i>
Auditorium (USI Università)	EB06	CUTANEOUS LYMPHOMAS W. Kempf, Zurich (Switzerland) <i>repeated on Friday, June 21, in Cinema Corso</i>
Aula Magna (USI Università)	EB03	BREAST IMPLANT ASSOCIATED ALCL AND OTHER RARE T-CELL LYMPHOMAS L. de Leval, Lausanne (Switzerland) <i>offered only once</i>
<b>10:15 – 10:35</b> Marquee, Cinema Corso, USI Università		<b>COFFEE BREAK</b>

10:35 – 12:00

**EDUCATIONAL SYMPOSIA** 🎤

*2 parallel sessions*

Room A, Cinema Corso,  
Auditorium and Aula Magna  
(USI Università)

**TREATING HODGKIN LYMPHOMA IN THE NEW MILLENNIUM**

Chair: A. Engert, Cologne (Germany)

- EB13 OPTIONS FOR FIRST LINE THERAPY OF HODGKIN LYMPHOMA  
P.W.M. Johnson, Southampton (UK)
- EB14 RELAPSED AND REFRACTORY DISEASE  
A.S. LaCasce, Boston, MA (USA)
- EB15 TREATMENT OF ELDERLY HODGKIN LYMPHOMA PATIENTS  
A. Engert, Cologne (Germany)

Room B  
and Marquee

**NEW DRUGS FOR NON-HODGKIN LYMPHOMA: BEYOND CHEMOTHERAPY**

Chair: G. Salles, Lyon (France)

- EB16 CAR T CELL THERAPY: FULL SPEED AHEAD  
R.J. Brentjens, New York, NY (USA)
- EB17 NEW DRUGS FOR OLD TARGETS  
G. Salles, Lyon (France)
- EB18 NEW DRUGS FOR NEW TARGETS  
A. Younes, New York, NY (USA)

12:00 – 17:00  
Marquee

Abstract Nr

**POSTER SESSION**

- 136 - 159 BIOLOGY AND PATHOLOGY
- 160 - 169 CLL
- 170 - 183 INDOLENT LYMPHOMAS
- 184 - 191 MANTLE CELL LYMPHOMAS
- 192 - 206 AGGRESSIVE LYMPHOMAS
- 207 - 217 EXTRANODAL LYMPHOMAS
- 218 - 233 PTCL AND NK/T CELL LYMPHOMAS
- 234 - 245 HODGKIN LYMPHOMAS
- 246 - 262 IMMUNOTHERAPY
- 263 - 285 NOVEL TREATMENTS

12:00 – 13:00  
Marquee

**LUNCH TIME AND POSTER VIEWING**

13:00 – 14:00

Room A, B, Marquee,  
Cinema Corso, Auditorium and  
Aula Magna (USI Università)

**OPENING OF THE CONFERENCE** 🎤

WELCOME AND INTRODUCTORY REMARKS

F. Cavalli, Bellinzona (Switzerland)

**HENRY KAPLAN MEMORIAL LECTURE AND SAN SALVATORE FOUNDATION PRIZE** 🎤

Introduction to San Salvatore Foundation: S. Coduri, Lugano (Switzerland)

Laudatio: R. Stahel, Zurich (Switzerland)

001

NEXT GENERATION CAR T CELLS FOR LYMPHOMA AND BEYOND

C.H. June, Philadelphia, PA (USA)

14:00 – 15:25

Room A, B, Marquee,  
Cinema Corso, Auditorium and  
Aula Magna (USI Università)

**PLENARY SESSION**

Co-chairs: J.O. Armitage, Omaha, NE (USA) and F. Cavalli, Bellinzona (Switzerland)

14:00	004	IDENTIFYING MUTATIONS ENRICHED IN RELAPSED-REFRACTORY DLBCL TO DERIVE GENETIC FACTORS UNDERLYING TREATMENT RESISTANCE C. Rushton, Burnaby, B.C (Canada)
14:15	005	ROBUST: FIRST REPORT OF PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP (R2-CHOP) VS PLACEBO/R-CHOP IN PREVIOUSLY UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA U. Vitolo, Turin (Italy)
14:30	006	ADDITION OF LENALIDOMIDE TO R-CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG-ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R-CHOP G.S. Nowakowski, Rochester, MN (USA)
14:45		Discussant for presentations 004, 005 and 006: M.A. Shipp, Boston, MA (USA)
15:00	007	IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL P. Langerbeins, Cologne (Germany)
15:15		Discussant for presentation 007: S.M. O'Brien, Irvine, CA (USA)
15:25 – 15:50 Marquee		<b>COFFEE BREAK</b>
15:50 – 16:50 Room A, B, Marquee, Cinema Corso, Auditorium and Aula Magna (USI Università)		<b>AACR-ICML JOINT SESSION - THE ROLE OF NON-CLINICAL MODELS AS BRIDGES TO EARLY CLINICAL TRIALS</b> Co-chairs: M. Foti, Philadelphia, PA (USA) and B. Nadel, Marseille (France)
15:50	008	DESIGNER ORGANOIDS FOR MODELING EPIGENETICS, SIGNALING, AND THERAPIES IN LYMPHOMA A. Singh, New York, NY (USA)
16:10	009	MOUSE PDX AS NON-CLINICAL MODELS FOR LYMPHOMA A. Louissaint, Boston, MA (USA)
16:30	010	ADVANCING OUR UNDERSTANDING AND TREATMENT OF LYMPHOMA WITH SPONTANEOUS CANINE MODELS L. Aresu, Turin (Italy)
17:05 – 18:05		<b>“FOCUS ON...” SESSIONS</b> <i>5 parallel sessions</i>
Room A		<b>MANTLE CELL LYMPHOMA</b> Chair: J.P. Leonard, New York, NY (USA)
17:05	011	COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL P. Jain, Houston, TX (USA)
17:15	012	IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R-HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL) M. Wang, Houston, TX (USA)

17:25	013	AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION-FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA A. Zoellner, Munich (Germany)
17:35	014	OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, RESULTS OF LYMA-101 TRIAL, A LYSA GROUP STUDY S. Le Gouill, Nantes (France)
17:45	015	ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA Y. Song, Beijing (China)
17:55	016	OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY C. Visco, Verona (Italy)
Room B		<b>PET IMAGING</b> Chair: B.D. Cheson, Washington, D.C. (USA)
17:05	017	A GENE EXPRESSION-BASED SCORE TO PREDICT INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD B. Donati, Reggio Emilia (Italy)
17:15	018	PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)-POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION M. Novo, Rochester, MN (USA)
17:25	019	HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY L. Vercellino, Paris (France)
17:35	020	BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL M. Trněný, Prague (Czech Republic)
17:45	021	RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY S. Chauvie, Cuneo (Italy)
17:55	022	PROGNOSTIC VALUE OF PRE-TREATMENT PET SCAN IN PATIENTS WITH FOLLICULAR LYMPHOMA RECEIVING FRONTLINE THERAPY P. Strati, Houston, TX (USA)
Cinema Corso		<b>PEDIATRIC LYMPHOMA</b> Chair: W. Wössmann, Hamburg (Germany)
17:05	023	NON-HODGKIN LYMPHOMA IN ADOLESCENT AND YOUNG ADULTS - A NATIONAL PROSPECTIVE POPULATION-BASED STUDY R. Carr, London (UK)

17:15	024	INCLUSION OF A PEDIATRIC PERSPECTIVE INTO RECOMMENDATIONS FOR THE INITIAL EVALUATION AND STAGING OF HODGKIN LYMPHOMA: A CALL TO ACTION FROM THE INTERNATIONAL SEARCH WORKING GROUP J. Flerlage, Memphis, TN (USA)
17:25	025	SAFETY AND RESPONSE AFTER 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL) J. Flerlage, Memphis, TN (USA)
17:35	026	RESPONSE-ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES K.M. Kelly, Buffalo, NY (USA)
17:45	027	IBRUTINIB + CHEMOIMMUNOTHERAPY (CIT) FOR RELAPSED/REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL) IN CHILDREN (SPARKLE TRIAL): INITIAL SAFETY, PK, AND EFFICACY A. Burke, Cambridge (UK)
17:55	028	CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR REFRACTORY AND RELAPSED BURKITT'S LYMPHOMA, EARLY RESPONSE IN PEDIATRIC PATIENTS W.Q. Zhang, Beijing (China)
Auditorium (USI Università)		<b>RESULTS FROM SINGLE AGENT TRIALS</b> Chair: C. Thieblemont, Paris (France)
17:05	029	PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA K.A. Rogers, Columbus, OH (USA)
17:15	030	RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA—ALONE OR IN COMBINATION WITH RITUXIMAB S.D. Smith, Seattle, WA (USA)
17:25	031	A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) N. Kalakonda, Liverpool (UK)
17:35	032	TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY T.E. Witzig, Rochester, MN (USA)
17:45	033	DUVELISIB, AN ORAL DUAL PI3K- $\delta,\gamma$ INHIBITOR, EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) PERIPHERAL T-CELL LYMPHOMA: RATIONALE FOR THE PHASE 2 PRIMO TRIAL S.M. Horwitz, New York, NY (USA)
17:55	034	EFFICACY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH LESS ADVANCED MYCOSIS FUNGOIDES: RESULTS FROM THE MAVORIC STUDY J. Scarisbrick, Birmingham (UK)

**ONGOING TRIALS**

Chair: J.M. Vose, Omaha, NE (USA)

- |       |      |   |
|-------|------|---|
| 17:05 | OT01 | NCRI PETReA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA<br>A.R. Pettitt, Liverpool (UK)   |
| 17:15 | OT02 | POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R-CHP VERSUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL<br>H. Tilly, Rouen (France)  |
| 17:25 | OT03 | PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R-CHOP VS PLACEBO/R-CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)<br>J. Zhu, Beijing (China)  |
| 17:35 | OT04 | THE DIAL STUDY (DUAL IMMUNOMODULATION IN AGGRESSIVE LYMPHOMA): RANDOMIZED PHASE 2 TRIAL OF VARLILUMAB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS<br>J.C. Villasboas, Rochester, MN (USA)   |
| 17:45 | OT05 | ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRIStINE AND PREDNISOLONE (R-CHOP) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)<br>T. Cummin, Southampton (UK)  |
| 17:55 | OT06 | TELLOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY: AN OPEN LABEL, MULTI-COHORT, MULTI-CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA<br>P. Porcu, Philadelphia, PA (USA) |

---

## Thursday, June 20, 2019

---

08:00 – 08:45		<b>MEET THE PROFESSOR SESSIONS</b> 🏢 <i>5 parallel sessions</i>
Room A	EB10	THE MODERN APPROACH TO MANTLE CELL LYMPHOMA S. Rule, Plymouth (UK)
Room B	EB09	MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD? S.V. Rajkumar, Rochester, MN (USA)
Cinema Corso	EB01	PCNSL, A CURABLE DISEASE T.T. Batchelor, Boston, MA (USA)
Auditorium (USI Università)	EB11	LIQUID BIOPSY IN NON-HODGKIN'S LYMPHOMA W.H. Wilson, Bethesda, MD (USA)
Aula Magna (USI Università)	EB04	NEW TREATMENT OPTIONS IN HAIRY CELL LEUKEMIA WITH FOCUS ON BRAF INHIBITORS B. Falini, Perugia (Italy) <i>offered only once</i>
09:00 – 17.00 Marquee		<b>POSTER SESSION</b>
09:00 – 10:30		<b>“CASE DISCUSSION” SESSIONS: Spain vs Texas (USA)</b> <i>4 parallel sessions</i>
Room A		<b>DLBCL</b> Chair: L.H. Sehn, Vancouver, B.C. (Canada) Discussants: E. Giné Soca, Barcelona vs J.R. Westin, Houston
Cinema Corso		<b>HODGKIN LYMPHOMA</b> Chair: A.S. LaCasce, Boston, MA (USA) Discussants: A.M. Sureda Balari, Barcelona vs H.J. Lee, Houston
Auditorium (USI Università)		<b>RADIOTHERAPY FOR LYMPHOMAS</b> Chair: L. Specht, Copenhagen (Denmark) Discussants: T. Illidge, Manchester (UK) vs B.S. Dabaja, Houston
Aula Magna (USI Università)		<b>DIFFICULT PATHOLOGICAL CASES</b> Chair: M. Ghielmini, Bellinzona (Switzerland) Presenters: E. Campo, Barcelona (Spain), S. Dirnhofer, Basel (Switzerland) and P. Gaulard, Paris (France) Discussants: A. Lopez-Guillermo, Barcelona vs R. Hagemeister, Houston
09:00 – 10:30 Room B and Marquee	Abstract Nr	<b>SESSION 1 – DLBCL: BIOLOGY</b> Co-chairs: R. Dalla-Favera, New York, NY (USA) and R. Küppers, Essen (Germany)
09:00	035	AN AUTOCHTHONOUS MOUSE MODEL OF MYD88 P.L265P- AND BCL2-DRIVEN DIFFUSE LARGE B CELL LYMPHOMA G. Knittel, Cologne (Germany)
09:15	036	CRYPTIC MYC AND BCL2 REARRANGEMENTS ARE AMONG A RANGE OF GENETIC MECHANISMS UNDERLYING THE DOUBLE HIT SIGNATURE IN NON- DOUBLE HIT DIFFUSE LARGE B-CELL LYMPHOMA L.K. Hilton, Burnaby, B.C. (Canada)

09:30	037	FUNCTIONAL CHARACTERIZATION OF NFKBIZ 3' UTR MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA S.E. Arthur, Burnaby, B.C. (Canada)
09:45	038	THE TRANSCRIPTION FACTOR FLI1 SUSTAINS RELEVANT BIOLOGICAL PATHWAYS AND DRIVES ONCOGENES THAT PROMOTE CELL GROWTH IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) G. Sartori, Bellinzona (Switzerland)
10:00	039	TRANSCRIPTIONAL AND GENOMIC INTRA-TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA T. Roider, Heidelberg (Germany)
10:15	040	THE NONCODING RNA GECPAR IS INVOLVED IN WNT SIGNALING AND HAS TUMOR-SUPPRESSOR ACTIVITY IN DIFFUSE LARGE B CELL LYMPHOMA S. Napoli, Bellinzona (Switzerland)
10:30 – 11:00 Marquee, Cinema Corso, USI Università		<b>COFFEE BREAK</b>
11:00 – 12:00 Room A, B, Marquee, Cinema Corso, Auditorium and Aula Magna (USI Università)		<b>SESSION 2 – DLBCL: CLINICAL DATA</b> Co-chairs: M. Trněný, Prague (Czech Republic) and W. Zhao, Shanghai (China)
11:00	041	INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT L. Ceriani, Bellinzona (Switzerland)
11:15	042	SMART START: RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE PRIOR TO COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA J.R. Westin, Houston, TX (USA)
11:30	043	RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY P. Lugtenburg, Rotterdam (Netherlands)
11:45	044	IMPAIRED IMMUNE HEALTH IN SURVIVORS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A LARGE POPULATION-BASED STUDY T. Shree, Stanford, CA (USA)
12:00 – 13:00 Marquee		<b>LUNCH TIME AND POSTER VIEWING</b> <i>from 12:30 to 13:00 authors in front of their poster for discussion with attendees</i>
13:00 – 13:45 Room A, B, Marquee, Cinema Corso and Aula Magna (USI Università)		<b>GIANNI BONADONNA MEMORIAL LECTURE</b> 🎤 <i>sponsored by the American Association for Cancer Research – AACR</i>  Laudatio: M.A. Shipp, Boston, MA (USA)
	002	PRECISION EPIGENETIC THERAPY FOR B-CELL LYMPHOMA A.M. Melnick, New York, NY (USA)

13:45 – 15:15  
Room A, B, Marquee,  
Cinema Corso, Auditorium  
and Aula Magna (USI  
Università)

### **SESSION 3 – CLL**

Chairs: J.F. Seymour, Melbourne (Australia) and M. Hallek, Cologne (Germany)

- 13:45            045            INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A)  
A. Condoluci, Bellinzona (Switzerland)
- 14:00            046            FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES  
K. Fischer, Cologne (Germany)
- 14:15            047            GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY  
E. Tausch, Ulm (Germany)  
*Best abstract submitted by a young investigator/travel grant recipient*
- 14:30            048            ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB (IR) OR BENDAMUSTINE (BR) BY INVESTIGATOR CHOICE IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA: PHASE 3 ASCEND STUDY  
P. Ghia, Milan (Italy)
- 14:45            049            ZANUBRUTINIB FOR PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA  
W. Xu, Nanjing (China)
- 15:00            050            A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY  
A.R. Mato, New York, NY (USA)

15:15 – 15:40  
Marquee

### **COFFEE BREAK**

15:40 – 16:55            2 parallel sessions

Room A, Cinema Corso  
Auditorium and Aula Magna  
(USI Università)

### **SESSION 4 – TREATMENT WITH NOVEL ANTIBODIES**

Co-chairs: D.G. Maloney, Seattle, WA (USA) and P.L. Zinzani, Bologna (Italy)

- 15:40            051            THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS  
R.H. Advani, Stanford, CA (USA)
- 15:55            052            CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)  
M.S. Topp, Würzburg (Germany)

16:10	053	CD20-TCB (RG6026), A NOVEL “2:1” FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA M.J. Dickinson, Melbourne (Australia)
16:25	054	ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT-402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA J. Radford, Manchester (UK)
16:40	055	ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT-301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) G. Collins, Oxford (UK)
15:40 – 16:55 Room B and Marquee		<b>SESSION 5 – T-CELL LYMPHOMAS</b> Co-chairs: S. Luminari, Reggio Emilia (Italy) and K.J. Savage, Vancouver, B.C. (Canada)
15:40	056	RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS. P. Ghione, New York, NY (USA)
15:55	057	AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY M. Lopez-Parra, Salamanca (Spain)
16:10	058	FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY O. Tournilhac, Clermont-Ferrand (France)
16:25	059	TREATMENT BENEFIT ASSOCIATING WITH NON-ANTHRACYCLINE CHEMOTHERAPY IN EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE S. Qi, Beijing (China)
16:40	060	SINTILIMAB FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A MULTICENTER, SINGLE-ARM, PHASE 2 TRIAL (ORIENT-4) R. Tao, Shanghai (China)
17:05 – 18:05		<b>“FOCUS ON...” SESSIONS</b> <i>5 parallel sessions</i>
Room A		<b>CLL AND MORE</b> Chair: D. Rossi, Bellinzona (Switzerland)
17:05	061	FIVE-YEAR FOLLOW-UP OF FIRST-LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA A. Tedeschi, Milan (Italy)
17:15	062	HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL O. Al-Sawaf, Cologne (Germany)

- 17:25 063 IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY  
J. Wu, San Francisco, CA (USA)
- 17:35 064 AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL  
S. Handunnetti, Melbourne (Australia)
- 17:45 065 TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA  
T. Siddiqi, Duarte, CA (USA)
- 17:55 066 THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL  
E. Tiacci, Perugia (Italy)
- Room B **CHEMOTHERAPY-FREE STRATEGIES**  
Chair: J.W. Friedberg, Rochester, NY (USA)
- 17:05 067 PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY-FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK)  
A. Moccia, Bellinzona (Switzerland)
- 17:15 068 EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL  
F. Morschhauser, Lille (France)
- 17:25 069 AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS  
J.P. Leonard, New York, NY (USA)
- 17:35 070 INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA  
J. Sharman, Eugene, OR (USA)
- 17:45 071 RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY  
M.H. Delfau-Larue, Creteil (France)
- 17:55 072 SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS.  
A. Stathis, Bellinzona (Switzerland)
- Cinema Corso **NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS**  
Chair: A. Davies, Southampton (UK)
- 17:05 073 PHASE I/II STUDY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB (TG-1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION  
A.R. Mato, New York, NY (USA)

- 17:15 074 PEMBROLIZUMAB WITH RCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL AND GRADE 3B FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE I TRIAL  
S.D. Smith, Seattle, WA (USA)
- 17:25 075 ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)  
C.S. Tam, Melbourne (Australia)
- 17 :35 076 A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW-GRADE B-CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS  
T. Shree, Stanford, CA (USA)
- 17:45 077 EXTENDED FOLLOW-UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN RESEARCH GROUP (E4412)  
C. Diefenbach, New York, NY (USA)
- 17:55 078 HIGH EXPRESSION OF BCL-2 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA CONFER POOR PROGNOSIS BUT MAY BE REVERSIBLE BY COMBINED INHIBITION WITH BET INHIBITORS AND BH3 MIMETICS.  
T.E. Cummin, Southampton (UK)
- Auditorium (USI Università) **NON-CLINICAL NEW DRUGS**  
Chair: L. Pasqualucci, New York, NY (USA)
- 17:05 079 FIRST-IN-CLASS HAT ACTIVATOR HIGHLY SYNERGISTIC WITH PAN-HDAC INHIBITOR ROMIDEPSIN LEADING TO PROFOUND HISTONE ACETYLATION CYTOTOXICITY  
Y. Liu, New York, NY (USA)
- 17:15 080 COPANLISIB AND VOLASERTIB OVERCOME IBRUTINIB-VENETOCLAX RESISTANCE VIA TARGETING PI3K-AKT SIGNALING AND G2/M CELL CYCLE TRANSITION IN MANTLE CELL LYMPHOMA  
R. Zhang, Houston, TX (USA)
- 17:25 081 THE LANDSCAPE OF DRUG PERTUBATION EFFECTS IN LEUKEMIA AND LYMPHOMA  
T. Zenz, Zurich (Switzerland)
- 17 :35 082 DISCOVERY OF A NOVEL, POTENTIAL FIRST-IN-CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS  
U. Philippar, Bersee (Belgium)
- 17:45 083 KYM-001, A FIRST-IN-CLASS ORAL IRAK4 PROTEIN DEGRADER, INDUCES TUMOR REGRESSION IN XENOGRAFT MODELS OF MYD88-MUTANT ABC DLBCL ALONE AND IN COMBINATION WITH BTK INHIBITION  
J. Kelleher, Cambridge, MA (USA)
- 17:55 084 THE ANTIBODY-DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT-402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI-LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION  
C. Tarantelli, Bellinzona (Switzerland)

**HIGH RISK LARGE B-CELL LYMPHOMAS**

Chair: L.H. Sehn, Vancouver, B.C. (Canada)

- 17:05 085 EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV-SPECIFIC CTL AND IBRUTINIB THERAPY  
M.K. Gandhi, Brisbane (Australia)
- 17:15 086 YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS  
S. Leppä, Helsinki (Finland)
- 17:25 087 SAFETY AND EFFICACY OF THE PD-L1 INHIBITOR DURVALUMAB WITH R-CHOP OR R2-CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH-RISK DLBCL  
G.S. Nowakowski, Rochester, MN (USA)
- 17 :35 088 INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE-ADJUSTED R-EPOCH FOR PATIENTS WITH RICHTER'S SYNDROME (CRC-043)  
M.S. Davids, Boston, MA (USA)
- 17:45 089 IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY  
F. Morschhauser, Lille (France)
- 17:55 090 CD19-DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES  
E.A. Chong, Philadelphia, PA (USA)

---

## Friday, June 21, 2019

---

08:00 – 08:45

### MEET THE PROFESSOR SESSIONS 🏢

*5 parallel sessions*

Room A	EB05	HOW TO APPROACH CLL IN CLINICAL PRACTICE M. Hallek, Cologne (Germany)
Room B	EB02	DOUBLE HIT LYMPHOMA, SO WHAT? A. Davies, Southampton (UK)
Cinema Corso	EB06	CUTANEOUS LYMPHOMAS W. Kempf, Zurich (Switzerland)
Auditorium (USI Università)	EB07	MANAGING THE TOXICITIES OF CAR T-CELL THERAPY S.S. Neelapu, Houston, TX (USA)
Aula Magna (USI Università)	EB08	RARE B CELL LYMPHOMAS IN CHILDREN AND ADOLESCENTS L. Quintanilla-Martinez de Fend, Tübingen (Germany) and W. Wössmann, Hamburg (Germany) <i>offered only once</i>

09:00 – 18:30  
Marquee

### POSTER SESSION

09:00 – 10:30

### “CASE DISCUSSION” SESSIONS: Spain vs Texas (USA)

*3 parallel sessions*

Room A	<b>FL/ INDOLENT LYMPHOMA</b> Chair: S. Rule, Plymouth (UK) Discussants: M. Provencio Pulla, Madrid vs L.J. Nastoupil, Houston
Cinema Corso	<b>CLL</b> Chair: S. O'Brien, Irvine, CA (USA) Discussants: J. Delgado, Barcelona vs P.A. Thompson, Houston
Aula Magna (USI Università)	<b>PTCL</b> Chair: K.J. Savage, Vancouver, B.C. (Canada) Discussants: A. Martín, Salamanca vs N.H. Fowler, Houston

09:00 – 10:30

Room B and Marquee

### SESSION 6 – LYMPHOMA PATHOLOGY

Co-chairs: K. Ohshima, Kurume (Japan) and E. Campo, Barcelona (Spain)

09:00	091	DIAGNOSIS AND CLASSIFICATION ASSISTANCE FROM LYMPHOMA MICROSCOPIC IMAGES USING DEEP LEARNING P. Brousset, Toulouse (France)
09:15	092	INTEGRATING TUMOR- AND MICROENVIRONMENT-REFLECTING GENES IN A UNIQUE AND ROUTINE-APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL. S.A. Pileri, Milan (Italy)
09:30	093	CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL S. Balasubramanian, San Diego CA (USA)

09:45	094	LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA S. Araf, London (UK)
10:00	095	DEFINING BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION IN A SPECIALISED UK HAEMATOPATHOLOGY DIAGNOSTIC SERVICE S. Barrans, Leeds (UK)
10:15	096	GENOME WIDE-ANALYSIS OF T(14;18)-NEGATIVE FOLLICULAR LYMPHOMA L. Quintanilla-Martinez de Fend, Tübingen (Germany)
09:00 – 12:00 Auditorium (USI Università)		<b>WORKSHOP – CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES</b> Organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG <b>open to all 15-ICML attendees</b>  <b>Part 1: FRACTIONATION ISSUES IN RADIOTHERAPY OF LYMPHOMAS</b> Chair: M.K. Gospodarowicz, Toronto, ON (Canada)
09:00		DOSE PER FRACTION, RESPONSE, LATE EFFECTS RELATIONSHIP IN LYMPHOMAS R. Hoppe, Stanford, CA (USA)
09:20		OPTIMAL DOSE FRACTIONATION FOR INDOLENT AND AGGRESSIVE LYMPHOMAS P. Hoskin, London and Manchester (UK)
09:40		OPTIMAL DOSE FRACTIONATION IN HODGKIN LYMPHOMAS C. Baues, Cologne (Germany)
10:00 – 10:25		<b>COFFEE BREAK</b> <i>inside Auditorium (USI Università), for attendees</i>
10:25		<b>Part 2: RADIOTHERAPY IN THE ELDERLY LYMPHOMA PATIENT</b> LYMPHOMA IN THE ELDERLY - SCOPE OF THE PROBLEMS I. Glimelius, Uppsala (Sweden)
10:45		RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: INDOLENT LYMPHOMAS U. Ricardi, Turin (Italy)
11:00		RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: AGGRESSIVE LYMPHOMA J. Yahalom, New York, NY (USA)
11:15		RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: HODGKIN LYMPHOMA L. Specht, Copenhagen (Denmark)
11:30		RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: LATE EFFECTS D. Hodgson, Toronto, ON (Canada)
11:45		QUESTIONS
10:30 – 11:00 Marquee, Cinema Corso, USI Università		<b>COFFEE BREAK</b>

11:00 – 12:00  
Room A, B, Marquee,  
Cinema Corso and Aula  
Magna (USI Università)

### **SESSION 7 – HODGKIN LYMPHOMA**

Co-chairs: R.H. Advani, Stanford, CA (USA) and T.A. Lister, London (UK)

- 11:00 097 STAGE I-II NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA IN THE MODERN ERA: A MULTI-INSTITUTIONAL EXPERIENCE OF ADULT PATIENTS BY ILROG  
M.S. Binkley, Stanford, CA (USA)
- 11:15 098 NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2-YEAR FOLLOW-UP  
S. Ansell, Rochester, MN (USA)
- 11:30 099 CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL  
A. Gallamini, Nice (France)
- 11:45 100 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA  
A. Prica, Toronto, ON (Canada)

12:00 – 13:00  
Marquee

### **LUNCH TIME AND POSTER VIEWING**

*from 12:30 to 13:00 authors in front of their poster for discussion with attendees*

13:00 – 13:45  
Room A, B,  
Marquee,  
Cinema Corso  
and Aula Magna  
(USI Università)

### **JOHN ULTMANN MEMORIAL LECTURE** 🎬

*sponsored by the European School of Oncology – ESO*

Laudatio: J.M. Vose, Omaha, NE (USA)

- 003 THIRTY YEARS OF T-CELL LYMPHOMAS  
P. Gaulard, Créteil (France)

13:45 – 15:00

*4 parallel sessions*

Room A  
and Cinema Corso

### **SESSION 8 – FOLLICULAR LYMPHOMA**

Co-chairs: B.S. Kahl, St. Louis, MO (USA) and M. Herold, Erfurt (Germany)

- 13:45 101 PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY; A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL  
S. Dimhofer, Basel (Switzerland)
- 14:00 102 DECIPHERING THE CONTRIBUTION OF MACROPHAGES TO FOLLICULAR LYMPHOMA PATHOGENESIS: NEW INSIGHTS INTO THERAPY  
P. Perez Galan, Barcelona (Spain)
- 14:15 103 IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA  
C.L. Batlevi, New York, NY (USA)
- 14:30 104 RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI  
M. Federico, Modena (Italy)

14:45	105	INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA F. Morschhauser, Lille (France)
Room B and Marquee		<b>SESSION 9 - EXTRANODAL LYMPHOMAS</b> Co-chairs: M.K. Gospodarowicz, Toronto, ON (Canada) and E. Zucca, Bellinzona (Switzerland)
13:45	106	INTEGRATIVE GENOMIC ANALYSIS IDENTIFIES KEY PATHOGENIC CONCEPTS IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA A. Mottok, Ulm (Germany)
14:00	107	OUTCOME OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET-GUIDED APPROACH A. Hayden, Vancouver, B.C. (Canada)
14:15	108	NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY P.L. Zinzani, Bologna (Italy)
14:30	109	R-CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL A.J. Ferreri, Milan (Italy)
14:45	110	POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) AFTER SOLID ORGAN TRANSPLANT (SOT): SURVIVAL AND PROGNOSTICATION AMONG 570 PATIENTS (PTS) TREATED IN THE MODERN ERA D. Jagadeesh, Cleveland, OH (USA)
14:15 – 17:30 Auditorium (USI Università)		<b>IBSA FOUNDATION SPECIAL FORUM - REVOLUTIONARY THERAPIES FOR CANCER</b> Chairmen: F. Cavalli, Bellinzona (Switzerland) and A. Alimonti, Bellinzona (Switzerland) Organized by IBSA Foundation for Scientific Research <b>Open to all 15-ICML attendees, appreciated pre-registration at <a href="http://www.ibsafoundation.org">www.ibsafoundation.org</a> (free session)</b>
14:15		WELCOME AND INTRODUCTION S. Misiti, IBSA Foundation A. Alimonti, IBSA Foundation Scientific Board
14:30		mTOR SIGNALING IN GROWTH AND METABOLISM M. Hall, Basel (Switzerland)
15:00		INNATE IMMUNITY, INFLAMMATION AND CANCER: FROM BENCH TO BEDSIDE A. Mantovani, Milan (Italy), London (UK)
15:30		BUILDING NEXT GENERATION CAR T CELLS C.H. June, Philadelphia, PA (USA)
16:00		FROM MOLECULAR ADDICTION TO IMMUNE ACTIVATION: REINVENTING THERAPIES FOR CANCER S. Peters, Lausanne (Switzerland)

14:15 – 17:15 Aula Magna (USI Università)		<b>UCLI-ICML JOINT SESSION – NEW DATA ON T-CELL AND OTHER LYMPHOMAS</b> Honorary Presidents: F. Cavalli, Bellinzona (Switzerland) and J. Ma, Harbin (China) Executive Presidents: W.J. Chng, Singapore (Singapore), J. M. Vose, Omaha, NE (USA), J. Zhu, Beijing (China)
14:20	111	20-YEAR SURVIVAL DATA ANALYSIS OF PTCL PATIENTS IN PEKING UNIVERSITY CANCER HOSPITAL Y. Song, Beijing (China)
14:45	112	DEVELOPING IMMUNOEPIGENETIC PLATFORMS FOR PTCL: LEVERAGING A LOGIC FOR PD1/PDL-1 INHIBITORS O.A. O'Connor, New York, NY (USA)
15:10	113	CLINICAL OUTCOME OF AN PROSPECTIVE, MULTICENTRE, RANDOMIZED, PHASE III NON-INFERIORITY CLINICAL TRIAL FOR PATIENTS WITH EXTRANODAL NK/T CELL LYMPHOMA TREATED BY P-GEMOX OR ASPAMETDEX H. Huang, Guangzhou (China)
15:35 – 15:55		<b>COFFEE BREAK</b> <i>inside Aula Magna (USI Università), for attendees</i>
15:55	114	NEW DATA IN THE MOLECULAR PATHOLOGY OF T CELL LYMPHOMAS L. de Leval, Lausanne (Switzerland)
16:20	115	DIFFUSE LARGE B-CELL LYMPHOMA: USING IMMUNE BIOMARKERS TO DEFINE NOVEL THERAPIES W. Zhao, Shanghai (China)
16:45	116	THE RELEVANCE OF OBSERVATIONAL REGISTRIES: THE CASE OF T CELL LYMPHOMA PROJECTS 1.0 AND 2.0 M. Federico, Modena (Italy)
15:00 – 15:30 Marquee		<b>COFFEE BREAK</b>
15:30 – 15:45 Room A, B, Marquee and Cinema Corso		<b>REPORT OF THE 15-ICML WORKSHOP</b> Co-chairs: S.S. Neelapu, Houston, TX (USA) and G. Salles, Lyon (France)  BRIDGING LIQUID BIOPSY INTO MANAGEMENT OF LYMPHOMA PATIENTS: DEVELOPMENT OF FRAMEWORKS FOR CLINICAL RESEARCH AND RECOMMENDATIONS FOR CLINICAL PRACTICE W.H. Wilson, Bethesda, MD (USA)
15:45 – 17:15 Room A, B, Marquee and Cinema Corso		<b>SESSION 10 – ADVANCES IN CAR-T CELL TREATMENT</b> Co-chairs: S.S. Neelapu, Houston, TX (USA) and G. Salles, Lyon (France)
15:45	117	NOVEL BAFF-R CAR T-CELL THERAPY FOR CD19 ANTIGEN-LOSS RELAPSED B CELL TUMORS L.W. Kwak, Duarte, CA (USA)
16:00	118	PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION C.L. Batlevi, New York, NY (USA)
16:15	119	CD30-CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF HODGKIN LYMPHOMA (HL) C.A. Ramos, Houston, TX (USA)

16:30	120	DURABLE RESPONSES AFTER CD19-TARGETED CAR-T CELL IMMUNOTHERAPY WITH CONCURRENT IBRUTINIB FOR CLL AFTER PRIOR IBRUTINIB FAILURE J. Gauthier, Seattle, WA (USA)
16:45	121	HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR-T CELL IMMUNOTHERAPY A.V. Hirayama, Seattle, WA (USA)
17:00	122	SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY T. Siddiqi, Duarte, CA (USA)
17:15 – 17:35 Room A, B, Marquee and Cinema Corso		<b>SPECIAL LECTURE</b> Chair: F. Cavalli, Bellinzona (Switzerland)
	123	THE HIGH COST OF CANCER DRUGS: WHAT CAN WE DO? S.V. Rajkumar, Rochester, MN (USA)
17:35 – 18:30 Marquee		<b>FAREWELL APERO</b>

---

## Saturday, June 22, 2019

---

- 08:30 – 10:30  
Auditorium  
(USI Università)
- ESO – ESMIT Educational Session - PET-CT IN LYMPHOMA**  
Chair: A.T. Lister, London (UK)  
Organized by the European School of Oncology – ESO and the European School of Multimodality Imaging & Therapy – ESMIT  
**Open to all 15-ICML attendees**
- 08:30 HOW TO INTERPRET PET-CT SCANS IN LYMPHOMAS: VISUAL AND FUNCTIONAL EVALUATION  
M. Meignan, Creteil (France)
- 08:50 PET-BASED CLINICAL DECISIONS: WHERE DO WE STAND AND WHERE WE MAY GO  
P.W.M. Johnson, Southampton (UK)
- 09:20 THE LUGANO CLASSIFICATION 5 YEARS AFTER: SHOULD WE CHANGE ANYTHING?  
B.D. Cheson, Washington, D.C. (USA)
- 09:40 CHALLENGING CASES FROM THE ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND  
Presented by E. Zucca, Bellinzona (Switzerland) and L. Ceriani, Bellinzona (Switzerland)  
Discussants: A.T. Lister, London (UK) and all faculty
- 08:30 – 10:00  
Room A and B
- SESSION 11 – NEW DRUG COMBINATIONS**  
Co-chairs: A. Younes, New York, NY (USA) and M. Dreyling, Munich (Germany)
- 08:30 124 PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND)  
G. Salles, Lyon (France)
- 08:45 125 BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA  
M. Dickinson, Melbourne (Australia)
- 09:00 126 POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS  
A. McMillan, Nottingham (UK)
- 09:15 127 THE PI3K $\Delta$  INHIBITOR ME-401  $\pm$  RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)  
A.D. Zelenetz, New York, NY (USA)
- 09:30 128 INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE  
S.M. Ansell, Rochester, MN (USA)
- 09:45 129 TARGETING THE PERIPHERAL T-CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5-AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL-MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY  
L. Falchi, New York, NY (USA)

10:15 – 11:15 Room A and B		<b>“FOCUS ON” SESSION - INDOLENT NON-FOLLICULAR LYMPHOMA</b> Chair: G.S. Nowakowski, Rochester, MN (USA)
10:15	130	EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT A. Conconi, Ponderano (Italy)
10:25	131	INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE “IRIS” TRIAL A.J. Ferreri, Milan (Italy)
10:35	132	MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY A. Brusca, Bellinzona (Switzerland)
10:45	133	UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY P.L. Zinzani, Bologna (Italy)
10:55	134	IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY J. Castillo, Boston, MA (USA)
11:05	135	IBRUTINIB MONOTHERAPY PRODUCES LONG-TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM'S MACROGLOBULINEMIA: FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821) S.P. Treon, Boston, MA (USA)
11:15 – 11:40 Room A and B		<b>15-ICML HIGHLIGHTS</b>  “TAKE HOME MESSAGES” J.W. Friedberg, Rochester, NY (USA)
11:40 – 11:50		CLOSURE AND FAREWELL F. Cavalli, Bellinzona (Switzerland)
13:30 – 18:00 Room B		<b>IV INTERNATIONAL WORKSHOP ON CANINE LYMPHOMA - HOW TO STAGE CANINE LYMPHOMA IN 2019</b> Co-chairs: L. Aresu, Turin (Italy), S. Comazzi, Milan (Italy), F. Guscelli, Zurich (Switzerland) and L. Marconato, Bologna (Italy) Organized by the European Canine Lymphoma Network <b>open to all 15-ICML attendees</b>

 This icon denotes presentations that will be audio- and video-recorded and available online, only for 15-ICML attendees, starting from July 2019, thanks to an unrestricted grant of a sponsor.

- Updated on May 22, 2019 -